Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias.

Cutler JA, Wells DA, van de Loosdrecht AA, de Baca ME, Kalnoski MH, Zehentner BK, Eidenschink L, Ghirardelli KM, Biggerstaff JS, Loken MR.

Cytometry B Clin Cytom. 2011 May;80(3):150-7. doi: 10.1002/cyto.b.20582. Epub 2010 Dec 23.

2.

Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.

Chu SC, Wang TF, Li CC, Kao RH, Li DK, Su YC, Wells DA, Loken MR.

Leuk Res. 2011 Jul;35(7):868-73. doi: 10.1016/j.leukres.2011.02.016. Epub 2011 Mar 12.

PMID:
21397943
3.
4.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2014 May;86(3):207-15. doi: 10.1002/cyto.b.21160. Epub 2014 Jan 28.

5.

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Br J Haematol. 2014 Oct;167(1):100-9. doi: 10.1111/bjh.12994. Epub 2014 Jun 30.

PMID:
24976502
6.

Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.

van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ.

Blood. 2008 Feb 1;111(3):1067-77. Epub 2007 Oct 30.

7.

The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure.

Jiang H, Xue Y, Wang Q, Pan J, Wu Y, Zhang J, Bai S, Wang Q, He G, Sun A, Wu D, Chen S.

Leuk Res. 2012 Apr;36(4):448-52. doi: 10.1016/j.leukres.2011.10.014. Epub 2011 Nov 1.

PMID:
22047706
8.

Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.

Lee HR, Oh B, Hong DS, Zang DY, Yoon HJ, Kim HJ, Kim I, Ahn JS, Cheong JW, Lee KA, Cho KS, Lee MH, Bang SM, Kim TY, Yun YM, Min YH, Lee YK, Lee DS; AML/MDS Working Party of the Korean Society of Hematology..

Cancer Genet Cytogenet. 2010 Dec;203(2):193-202. doi: 10.1016/j.cancergencyto.2010.08.007.

PMID:
21156233
9.

A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG)

Jaju RJ, Haas OA, Neat M, Harbott J, Saha V, Boultwood J, Brown JM, Pirc-Danoewinata H, Krings BW, Müller U, Morris SW, Wainscoat JS, Kearney L.

Blood. 1999 Jul 15;94(2):773-80.

11.
12.
13.

MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).

Nilsson T, Nilsson L, Lenhoff S, Rylander L, Astrand-Grundström I, Strömbeck B, Höglund M, Turesson I, Westin J, Mitelman F, Jacobsen SE, Johansson B.

Genes Chromosomes Cancer. 2004 Nov;41(3):223-31.

PMID:
15334545
14.

Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes.

Ma L, Delforge M, van Duppen V, Verhoef G, Emanuel B, Boogaerts M, Hagemeijer A, Vandenberghe P.

Leukemia. 2004 Sep;18(9):1451-6.

PMID:
15284864
15.

Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow.

McClintock-Treep SA, Briggs RC, Shults KE, Flye-Blakemore LA, Mosse CA, Jagasia MH, Shinar AA, Dupont WD, Stelzer GT, Head DR.

Am J Clin Pathol. 2011 Mar;135(3):380-5. doi: 10.1309/AJCP00SHTQCVUYRI.

PMID:
21350091
17.

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C.

Ann Hematol. 2009 Dec;88(12):1207-13. doi: 10.1007/s00277-009-0745-3. Epub 2009 May 5.

PMID:
19415278
19.
20.

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K.

Haematologica. 2012 Aug;97(8):1209-17. doi: 10.3324/haematol.2011.048421. Epub 2012 Feb 7.

Supplemental Content

Support Center